In 2010, Novo Nordisk breached the [[Association of the British Pharmaceutical Industry|ABPIs]] code of conduct by failing to provide information about side-effects of [[Victoza]] and by promoting [[Victoza]] prior to being granted market authorization.<ref>{{cite news|url=http://www.pmcpa.org.uk/?q=node/878|title=Novo Nordisk Limited, Eli Lilly and Company Limited, Grünenthal Ltd and Napp Pharmaceuticals Limited named in advertisements|publisher=Prescription Medicines Code of Practice Authority (PMCPA)|accessdate=2011-02-07}}</ref>

 
In March 2013, a debate emerged in which scientists questioned whether the incretin class of diabetes medications – the class to which [[Victoza]] belongs – had an increased risk of side effects in the pancreas such as pancreatitis and pancreatic cancer. It was concluded that data currently available did not confirm these concerns.<ref>{{Cite journal | doi = 10.1111/dom.12230| title = A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs| journal = Diabetes, Obesity and Metabolism| volume = 16| issue = 3| pages = 273| year = 2014| last1 = Funch | first1 = D.| last2 = Gydesen | first2 = H.| last3 = Tornøe | first3 = K.| last4 = Major-Pedersen | first4 = A.| last5 = Chan | first5 = K. A.}}</ref>
